Achilles Therapeutics (ACHL)
(Delayed Data from NSDQ)
$0.85 USD
+0.01 (1.32%)
Updated Jul 16, 2024 12:48 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Achilles Therapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 75 | 78 | 64 | 34 | 14 |
Income After Depreciation & Amortization | -75 | -78 | -64 | -34 | -14 |
Non-Operating Income | 6 | 7 | 3 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -69 | -71 | -61 | -33 | -14 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -70 | -71 | -61 | -33 | -14 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -70 | -71 | -61 | -33 | -14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -71 | -75 | -61 | -33 | -13 |
Depreciation & Amortization (Cash Flow) | 5 | 4 | 3 | 1 | 0 |
Income After Depreciation & Amortization | -75 | -78 | -64 | -34 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 39.97 | 39.14 | 28.66 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.74 | -1.82 | -2.13 | NA | NA |
Diluted Net EPS (GAAP) | -1.74 | -1.82 | -2.13 | -7.87 | NA |
Fiscal Year end for Achilles Therapeutics PLC Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 14.30 | 19.51 | 19.09 | 18.09 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -14.30 | -19.51 | -19.09 | -18.09 |
Non-Operating Income | NA | 2.00 | 1.39 | 2.39 | 1.21 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -12.30 | -18.13 | -16.71 | -16.88 |
Income Taxes | NA | -0.02 | 0.51 | -0.02 | -0.03 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -12.27 | -18.63 | -16.68 | -16.85 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -12.27 | -18.63 | -16.68 | -16.85 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 40.28 | 40.19 | 40.07 | 39.90 |
Diluted EPS Before Non-Recurring Items | NA | -0.30 | -0.46 | -0.42 | -0.42 |
Diluted Net EPS (GAAP) | NA | -0.30 | -0.46 | -0.42 | -0.42 |